Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe - Wikidata - awgldk - TriplyDB

Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe

Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe

http://www.wikidata.org/entity/Q30404728

about

Vaccines for preventing influenza in healthy adults Enhancing vaccine safety capacity globally: A lifecycle perspective Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how?Enhancing the work of the Department of Health and Human Services national vaccine program in global immunization: recommendations of the National Vaccine Advisory Committee: approved by the National Vaccine Advisory Committee on September 12, 2013 European decision-maker perspective with regard to influenza prevention policies.Frequently asked questions on seven rare adverse events following immunization.Guillain-Barré Syndrome, Influenza Vaccination, and Antecedent Respiratory and Gastrointestinal Infections: A Case-Centered Analysis in the Vaccine Safety Datalink, 2009-2011.An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.Guillain-Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines: a multinational self-controlled case series in Europe Pandemic A/H1N1 2009 influenza vaccination, preceding infections and clinical findings in UK children with Guillain-Barré syndrome.Risk of Guillain-Barré syndrome following pandemic influenza A(H1N1) 2009 vaccination in Germany Risk of Guillain-Barré syndrome after exposure to pandemic influenza A(H1N1)pdm09 vaccination or infection: a Norwegian population-based cohort study.Guillain-Barré syndrome following the 2009 pandemic monovalent and seasonal trivalent influenza vaccination campaigns in Spain from 2009 to 2011: outcomes from active surveillance by a neurologist network, and records from a country-wide hospital di The importance of influenza prevention for public health.Influenza vaccination coverage rate in children: reasons for a failure and how to go forward.[Guillain-Barré syndrome after exposure to influenza].Risk of presentation to hospital with epileptic seizures after vaccination with monovalent AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine (Pandemrix): self controlled case series study.Safety of AS03-adjuvanted split-virion H1N1 (2009) pandemic influenza vaccine: a prospective cohort study Safety of pandemic (H1N1) 2009 monovalent vaccines in taiwan: a self-controlled case series study.Data Extraction and Management in Networks of Observational Health Care Databases for Scientific Research: A Comparison of EU-ADR, OMOP, Mini-Sentinel and MATRICE Strategies.Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study.Clinical Features of Post-Vaccination Guillain-Barré Syndrome (GBS) in Korea.Comparatively low attendance during Human Papillomavirus catch-up vaccination among teenage girls in the Netherlands: Insights from a behavioral survey among parents.Ontology-based combinatorial comparative analysis of adverse events associated with killed and live influenza vaccines.Simulation study of the effect of influenza and influenza vaccination on risk of acquiring Guillain-Barré syndrome Changes in lymphocyte subsets in patients with Guillain-Barré syndrome treated with immunoglobulin.Seasonal influenza vaccination for children in Thailand: a cost-effectiveness analysis Hospital Admissions, Transfers and Costs of Guillain-Barré Syndrome.The complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccines.Guillain-Barré syndrome and anti-ganglioside antibodies: a clinician-scientist's journey.Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccination.Risk of Guillain-Barré syndrome after 2010-2011 influenza vaccination.Assessing the safety of influenza vaccination in specific populations: children and the elderly.The Innovative Medicines Initiative moves translational immunology forward.Dissecting the Role of Anti-ganglioside Antibodies in Guillain-Barré Syndrome: an Animal Model Approach.Vaccine Case-Population: A New Method for Vaccine Safety Surveillance.Strategies in recommending influenza vaccination in Europe and US.Did the influenza A (H1N1) 2009 monovalent inactivated vaccines increase the risk for Guillain-Barré syndrome?Preparing for a potential A(H7N9) pandemic: lessons from the deployment of A(H1N1) pandemic vaccines.Population incidence of Guillain-Barré syndrome in parts of China: three large populations in Jiangsu province, 2008-2010.

P2860

Q24197955-18AACDD1-04CF-487E-B6E4-229CCCE27554 Q26782451-E626D5AD-EB01-4876-9213-878FB17DC496 Q26996499-E3EA682A-3B06-46B9-92A6-0DE6496400E3 Q28654939-0F5D201D-19F9-4616-A8DA-3FF1DF1DE314 Q30151954-F0F3F7FF-743D-402D-89DA-8AC3FAE71487 Q30234430-FFE135C2-3FFF-40B5-AEF1-F07A5D3418CA Q30351998-4FBA887F-043E-42A6-879A-24CD27FEF89A Q30352329-1FFCC498-75C7-4ADC-93EA-EAD814481062 Q30357675-4C09DB00-E0A0-4FDF-8E23-5934CD6907EA Q30359657-7254CA2C-D4D8-471C-803E-28B9E060CC30 Q30362413-54DA03ED-45BF-4111-AD8E-6A94FD9B9B8B Q30374961-6EF127F5-8774-4421-BC2D-DE765E0978CC Q30388367-1F231BB5-4B44-493C-8F89-FDDD8C79CB7B Q30411857-D93A379C-A5B8-4F49-813A-9F7E2B1CD770 Q30411868-8500FE65-5943-481F-B701-57FE8A5833C4 Q30415924-30BB9D7B-DA6A-4E06-8280-7C61574AF86B Q30425209-E2542E93-33DB-449B-BC0F-AC72ED9CA5B3 Q30426869-397D4C97-3BA6-45D5-9293-9BE8D415A1BB Q30428839-1866C842-BA2A-42BF-AF05-D0FD1971A44E Q31063299-BF700491-FE0D-49C7-BE29-FF6E28B9C749 Q33403378-18CC9B54-1E4E-48D8-B794-5809D54B1DBC Q33770375-D7C75B6E-9982-4B84-B755-99C3104E0E80 Q34322484-7807C48F-08D2-4441-82E1-2D051125167D Q34499848-A2C4F7FF-6AEB-4C72-A089-248EABCFA6E1 Q35037338-E0B33DB6-BA06-47D4-AD2E-61F80BEDFE6D Q35331829-B2DB262F-0EC5-4D1F-B873-A2E2C7BB4154 Q35642206-A5BB885E-3B52-4916-B12D-54A9D53B050D Q35918443-48A532B5-9CDE-4D1F-966D-38D605F31920 Q36131193-32A5B809-A5B0-4687-8919-5D72AEB21BC5 Q36174702-2E2404FA-5A90-4F78-A36D-C29C0952BE8A Q36882923-71AB8D61-A6F9-4E4E-AF99-0860CD16136B Q36902462-4B584AD2-2678-44FC-B00E-BC0EE0164AA0 Q38045920-2BAA9ABE-1918-4488-AEDB-7CD9BF9C9ADC Q38093624-62497B08-C324-43CD-854E-DB7C9DE859C8 Q38587703-6B484FC4-591A-4EB5-881D-FAB3061EE8D9 Q38804897-1A63CEAD-04B2-4A28-83C0-192C758FFA92 Q41996993-D823A75E-6E95-44B6-A0FF-C9E59C2C7987 Q43700573-30EE42A7-2643-4491-967D-A5FAE045C2B2 Q43753114-D32241F6-F688-4DFB-AE7B-488C48EBB3A1 Q44927841-08DFC6A7-61AF-4704-93F6-35C79FDEA300

P2860

Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe

http://www.wikidata.org/entity/Q30404728

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

Guillain-Barre syndrome and ad ...... l case-control study in Europe

@ast

Guillain-Barre syndrome and ad ...... l case-control study in Europe

@en

type

label

Guillain-Barre syndrome and ad ...... l case-control study in Europe

@ast

Guillain-Barre syndrome and ad ...... l case-control study in Europe

@en

prefLabel

Guillain-Barre syndrome and ad ...... l case-control study in Europe

@ast

Guillain-Barre syndrome and ad ...... l case-control study in Europe

@en

P1433

Q30404728-BBDDDF38-C796-49DA-82E7-FA1F2AFC1A26

P1476

Q30404728-8868E9B5-992B-446F-9F42-501835EC593F

P2093

Q30404728-06AB5D4C-743A-4C57-BF97-698376F526A0

Q30404728-0DFFF3D2-507A-4257-AD5A-4DEC572F7763

Q30404728-3F26C48C-CDEF-4AF8-BCF7-F7B82508C28E

Q30404728-50B26C9E-C35E-4F21-9290-3AFAB5657A52

Q30404728-7E361154-5F34-487E-8CEC-00479E786A63

Q30404728-FB5EFFBA-55AE-4FF4-943A-0AA7C00ADE44

P2860

Q30404728-0591C821-3290-481D-86D2-1440E9DF5446

Q30404728-0889D1B3-B355-4CBF-A272-7C649CCD7C1F

Q30404728-0A90F920-345A-49FB-BD17-F9FF5BE48FB4

Q30404728-1252540D-AA98-483F-B93D-75F8FEBE9C96

Q30404728-1DC04D0C-043C-42F4-BF11-038340437106

Q30404728-22CA1E73-18FA-43B3-9E19-E5C48DC1E6C7

Q30404728-24492BD3-9D2E-47A2-83B9-0D239BCAF3AB

Q30404728-24C1C9D6-74CE-49C3-A2EA-8734281FE6A6

Q30404728-2555F93B-24B1-4F2B-B0E1-7A96D9BF2DDF

Q30404728-2974C21A-A5C9-46C8-8BEC-D82DF2D819C1

P304

Q30404728-A2C87117-D6B9-478E-85F1-6ED69B2F8D5A

P31

Q30404728-D91732B5-731B-4E10-B2B7-0E8D0F513DFC

P356

Q30404728-4BADD171-2501-4D66-82C5-3F44C7033B4C

P407

Q30404728-88500456-D982-4357-8979-6A07E168FE05

P478

Q30404728-6DFA25B7-77BF-4546-ACAE-17CEE6776AC8

P50

Q30404728-C55B3CED-88D5-4335-AB30-8D7B5EA04295

P577

Q30404728-4588F254-0CA5-416C-91FC-7A5A49600B06

P5875

Q30404728-000581B7-2EBF-4C5B-A330-F66AABD26F05

P698

Q30404728-DA70F26B-97C4-4F25-8E84-AF2BB7D8000E

P921

Q30404728-C14BCB5F-140C-4B35-A2A8-7A13CBA9CB14

Q30404728-D9297730-5657-440D-B84B-AC15BAEFFAC8

Q30404728-b3c53a68-499e-8df3-81fb-6d8d1d426ef5

Q30404728-ef6abbdf-4429-c389-fcfd-1553d73cf53c

P932

Q30404728-40E311E6-FB83-4EA4-9C9D-F3ACE3EAE077

P356

P1433

P1476

Guillain-Barre syndrome and ad ...... l case-control study in Europe

@en

P2093

Daniel Weibel

http://www.w3.org/2001/XMLSchema#string

Jeanne Dieleman

http://www.w3.org/2001/XMLSchema#string

Kari Johansen

http://www.w3.org/2001/XMLSchema#string

Miriam Sturkenboom

http://www.w3.org/2001/XMLSchema#string

Silvana Romio

http://www.w3.org/2001/XMLSchema#string

VAESCO-GBS Case-Control Study Group

http://www.w3.org/2001/XMLSchema#string

P2860

Guillain–Barré syndrome and Fisher syndrome: Case definitions and guidelines for collection, analysis, and presentation of immunization safety data

The spectrum of antecedent infections in Guillain-Barre syndrome: A case-control study

Modeling and variable selection in epidemiologic analysis

Guillain-Barré syndrome after exposure to influenza virus

Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome

Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials.

Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database.

Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project.

Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial.

Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial.

P304

d3908

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BMJ.D3908

http://www.w3.org/2001/XMLSchema#string

P407

P478

343

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-07-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51486562

http://www.w3.org/2001/XMLSchema#string

P698

21750072

http://www.w3.org/2001/XMLSchema#string

P921

influenza A virus subtype H1N1

Guillain–Barré Syndrome

P932

3134565

http://www.w3.org/2001/XMLSchema#string